Home > Boards > US Listed > Biotechs > Exact Sciences (EXAS)

Exact Sciences (EXAS) Stock Has 40% Upside From

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
realfast95 Member Profile
Member Level 
Followed By 55
Posts 15,709
Boards Moderated 0
Alias Born 11/29/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/1/2021 6:10:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/23/2021 6:43:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/23/2021 6:42:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/23/2021 6:42:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/23/2021 6:41:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/23/2021 6:40:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/23/2021 6:39:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/22/2021 6:02:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/22/2021 6:00:53 PM
Exact Sciences to participate in March investor conferences PR Newswire (US) - 2/22/2021 6:00:00 AM
Exact Sciences Falls 4% On Larger-Than-Feared 4Q Loss TipRanks - 2/17/2021 3:59:05 AM
Exact Sciences under pressure after earnings miss Seeking Alpha - 2/16/2021 5:52:19 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/16/2021 5:32:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/16/2021 4:16:02 PM
Exact Sciences EPS misses by $2.59, beats on revenue Seeking Alpha - 2/16/2021 4:08:39 PM
Exact Sciences Announces Fourth Quarter 2020 Results PR Newswire (US) - 2/16/2021 4:05:00 PM
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope's Genomics Institute, TGen PR Newswire (US) - 2/16/2021 4:05:00 PM
Schedule 13g Edgar (US Regulatory) - 2/16/2021 12:35:58 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 12:27:47 PM
Exact Sciences Q4 2020 Earnings Preview Seeking Alpha - 2/15/2021 5:35:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/9/2021 4:35:53 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/5/2021 7:55:00 AM
Exact Sciences schedules fourth quarter 2020 earnings call PR Newswire (US) - 2/1/2021 6:00:00 AM
Exact Sciences to participate in February investor conferences PR Newswire (US) - 2/1/2021 6:00:00 AM
Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology PR Newswire (US) - 1/13/2021 2:45:00 PM
realfast95 Member Level  Wednesday, 01/15/20 06:40:13 AM
Re: None
Post # of 630 
Exact Sciences (EXAS) Stock Has 40% Upside From Here, Says Analyst
Maya Sasson January 14, 2020

Exact Sciences’ (EXAS) preliminary quarterly results blew expectations out of the water.

Yesterday, the molecular diagnostics company released preliminary results for its fourth quarter that exceeded analysts’ estimates. Total revenue for the quarter is expected to land between $294 million and $296 million, reflecting a top-line beat of about $4 million to $6 million.

The better-than-expected outcome was primarily driven by its acquisition of Genomic Health, which was finalized back in November and gave it access to Oncotype DX gene expression tests that have been used in treatment decisions for over 1 million cancer patients globally. During the quarter, Oncotype DX test volume growth of 14%, or total test volume of 41,000, helped Genomic Health generate revenue of between $118 and $119 million, up 13% year-over-year.

On top of this, Cologuard, its FDA approved noninvasive, at-home colon cancer screening test, will most likely see revenue come in within the range of $229 million to $230 million. While this falls in line with the consensus estimate, BTIG analyst Amanda Murphy reminds investors that the difference between consensus and guidance is the highest it has been this year. She points out that “consensus for Cologuard revenue was at the high-end of management’s guidance range for the quarter.” If achieved, the figure would also represent a year-over-year increase of 61%.

Based on the expected Cologuard revenue, it isn’t surprising to the analyst, then, that volumes for the screening test are also expected to match the estimate. The results indicate Cologuard test volume of 477,000 could be in store. This, however, would not only come in above management’s guidance of between 465,000 to 475,000, but also reflect impressive growth of 63%.

While management isn’t offering any 2020 guidance before its earnings call in February, Murphy notes that the results reaffirm her already established bullish thesis. “Since Cologuard was approved in 2014, Exact has secured broad reimbursement coverage, developed a large and experienced sales force, increased its lab capacity to seven million tests per year, and made significant investments in IT infrastructure. We believe Cologuard is currently at an inflection point and expect the company to hit its long-term goal of 40% market penetration by the end of 2030,” she explained. The four-star analyst added, “While not explicitly included in our current valuation model, we are also optimistic around the potential for Exact’s liquid biopsy test for liver cancer.”

Bearing this in mind, Murphy maintained both a Buy rating as well as a $127 price target. This conveys her confidence in Exact’s ability to climb 40% higher in the next twelve months. (To watch Murphy’s track record, click here)

As for the rest of the Street? It turns out that other analysts wholeheartedly agree with the BTIG analyst. Out of 9 total analysts that have published a recommendation over the last three months, 100% see the stock as a Buy. This makes the consensus rating a unanimous Strong Buy. Not to mention the $123.56 average price target puts the upside potential just below Murphy’s forecast at 37%.

https://blog.tipranks.com/exact-sciences-exas-stock-has-40-upside-from-here-says-analyst/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences